Microvessels support engraftment and functionality of human islets and hESC-derived pancreatic progenitors in diabetes models.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34480863.
- Also identified by DOI 10.1016/j.stem.2021.08.001.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Islet transplantation is a promising treatment for type 1 diabetes (T1D), yet the low donor pool, poor islet engraftment, and life-long immunosuppression prevent it from becoming the standard of care. Human embryonic stem cell (hESC)-derived pancreatic cells could eliminate donor shortages, but interventions to improve graft survival are needed. Here, we enhanced subcutaneous engraftment by employing a unique vascularization strategy based on ready-made microvessels (MVs) isolated from the adipose tissue. This resulted in improved cell survival and effective glucose response of both human islets and hESC-derived pancreatic cells, which ameliorated preexisting diabetes in three mouse models of T1D.
Medical subject headings
- Diabetes Mellitus, Type 1
- Human Embryonic Stem Cells
- Islets of Langerhans
- Islets of Langerhans Transplantation